Evaluating biomarkers, such as estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor‐2 (HER2), in pathological specimens is crucial for guiding breast cancer treatment. The gene discussed is ERBB2; the disease is breast carcinoma.